Pharmacogenomics of open-angle glaucoma

Stephen Schwartz, Juan Ayala Haedo, Krishna Kishor, M. Elizabeth Fini

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Pharmacogenomics is an evolving research discipline within ophthalmology. An early application appears to involve open-angle glaucoma, a common cause of worldwide preventable blindness. Primary open-angle glaucoma is primarily treated with medications, and the two most common classes of drugs are β-adrenergic receptor antagonists and prostaglandin analogs. One small clinical trial has documented a pharmacogenomic relationship between polymorphisms in the β1-adrenergic receptor with the selective β 1-antagonist betaxolol. A second small clinical trial has documented a pharmacogenomic relationship between polymorphisms in the prostaglandin F receptor and the prostaglandin analog latanoprost. A small pilot study has not found any significant pharmacogenomic relationship between polymorphisms in the glucocorticoid receptor and intraocular pressure elevation following treatment with intravitreal triamcinolone acetonide. Pharmacogenomics may explain some of the well-documented variability in response to common glaucoma medications.

Original languageEnglish
Pages (from-to)121-125
Number of pages5
JournalCurrent Pharmacogenomics and Personalized Medicine
Volume6
Issue number2
StatePublished - Dec 1 2008

Fingerprint

Open Angle Glaucoma
Pharmacogenetics
Synthetic Prostaglandins
latanoprost
Betaxolol
Clinical Trials
Drug Receptors
Triamcinolone Acetonide
Adrenergic Antagonists
Glucocorticoid Receptors
Ophthalmology
Blindness
Intraocular Pressure
Glaucoma
Adrenergic Receptors
Research

ASJC Scopus subject areas

  • Genetics
  • Molecular Medicine
  • Pharmacology
  • Molecular Biology
  • Genetics(clinical)

Cite this

Pharmacogenomics of open-angle glaucoma. / Schwartz, Stephen; Ayala Haedo, Juan; Kishor, Krishna; Fini, M. Elizabeth.

In: Current Pharmacogenomics and Personalized Medicine, Vol. 6, No. 2, 01.12.2008, p. 121-125.

Research output: Contribution to journalArticle

Schwartz, Stephen ; Ayala Haedo, Juan ; Kishor, Krishna ; Fini, M. Elizabeth. / Pharmacogenomics of open-angle glaucoma. In: Current Pharmacogenomics and Personalized Medicine. 2008 ; Vol. 6, No. 2. pp. 121-125.
@article{2f41ffa9f3f54ad9888e6230e2d589c8,
title = "Pharmacogenomics of open-angle glaucoma",
abstract = "Pharmacogenomics is an evolving research discipline within ophthalmology. An early application appears to involve open-angle glaucoma, a common cause of worldwide preventable blindness. Primary open-angle glaucoma is primarily treated with medications, and the two most common classes of drugs are β-adrenergic receptor antagonists and prostaglandin analogs. One small clinical trial has documented a pharmacogenomic relationship between polymorphisms in the β1-adrenergic receptor with the selective β 1-antagonist betaxolol. A second small clinical trial has documented a pharmacogenomic relationship between polymorphisms in the prostaglandin F2α receptor and the prostaglandin analog latanoprost. A small pilot study has not found any significant pharmacogenomic relationship between polymorphisms in the glucocorticoid receptor and intraocular pressure elevation following treatment with intravitreal triamcinolone acetonide. Pharmacogenomics may explain some of the well-documented variability in response to common glaucoma medications.",
author = "Stephen Schwartz and {Ayala Haedo}, Juan and Krishna Kishor and Fini, {M. Elizabeth}",
year = "2008",
month = "12",
day = "1",
language = "English",
volume = "6",
pages = "121--125",
journal = "Current Pharmacogenomics and Personalized Medicine",
issn = "1875-6921",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Pharmacogenomics of open-angle glaucoma

AU - Schwartz, Stephen

AU - Ayala Haedo, Juan

AU - Kishor, Krishna

AU - Fini, M. Elizabeth

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Pharmacogenomics is an evolving research discipline within ophthalmology. An early application appears to involve open-angle glaucoma, a common cause of worldwide preventable blindness. Primary open-angle glaucoma is primarily treated with medications, and the two most common classes of drugs are β-adrenergic receptor antagonists and prostaglandin analogs. One small clinical trial has documented a pharmacogenomic relationship between polymorphisms in the β1-adrenergic receptor with the selective β 1-antagonist betaxolol. A second small clinical trial has documented a pharmacogenomic relationship between polymorphisms in the prostaglandin F2α receptor and the prostaglandin analog latanoprost. A small pilot study has not found any significant pharmacogenomic relationship between polymorphisms in the glucocorticoid receptor and intraocular pressure elevation following treatment with intravitreal triamcinolone acetonide. Pharmacogenomics may explain some of the well-documented variability in response to common glaucoma medications.

AB - Pharmacogenomics is an evolving research discipline within ophthalmology. An early application appears to involve open-angle glaucoma, a common cause of worldwide preventable blindness. Primary open-angle glaucoma is primarily treated with medications, and the two most common classes of drugs are β-adrenergic receptor antagonists and prostaglandin analogs. One small clinical trial has documented a pharmacogenomic relationship between polymorphisms in the β1-adrenergic receptor with the selective β 1-antagonist betaxolol. A second small clinical trial has documented a pharmacogenomic relationship between polymorphisms in the prostaglandin F2α receptor and the prostaglandin analog latanoprost. A small pilot study has not found any significant pharmacogenomic relationship between polymorphisms in the glucocorticoid receptor and intraocular pressure elevation following treatment with intravitreal triamcinolone acetonide. Pharmacogenomics may explain some of the well-documented variability in response to common glaucoma medications.

UR - http://www.scopus.com/inward/record.url?scp=56249088466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56249088466&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:56249088466

VL - 6

SP - 121

EP - 125

JO - Current Pharmacogenomics and Personalized Medicine

JF - Current Pharmacogenomics and Personalized Medicine

SN - 1875-6921

IS - 2

ER -